Cantor Fitzgerald Reiterates Overweight Rating for Vertex Pharmaceuticals (NASDAQ:VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “overweight” rating restated by equities researchers ...
Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
Hosted on MSN10mon
Vertex (VRTX) Down 0.2% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX ... Adjusted operating expense was $1.0 billion in the quarter, up 15% year over year. Adjusted R&D expenses ...
bovnews7d
Vertex Pharmaceuticals Inc (VRTX) Stock’s 0.04% Increase This Year: What’s the Story?
Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $422 which represents a slight increase of $5.04 or 1.21% from the prior close of $416.96. The stock opened at $422.73 ...
Nasdaq1mon
Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals
Also, high R&D expenses on advanced technologies ... (You can read the full research report on Vertex Pharmaceuticals here >>>) Shares of BK Technologies have outperformed the Zacks Wireless ...